---
schema_version: "secwatch.filing_event.v1"
accession: "0001099800-23-000003"
form_type: "8-K"
ticker: "EW"
cik: "0001099800"
company_name: "Edwards Lifesciences Corp"
filed_at: "2023-01-31T23:59:59+00:00"
generated_at: "2026-06-20T04:56:53.541993+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Edwards Q4 sales up 1% to $1.35B; adjusted EPS grows 25% to $0.64

## Summary
- Q4 TAVR sales flat at $868M; constant-currency growth 5%; U.S. procedures rose mid-single digits.
- Full-year 2022 sales $5.38B (+3%); adjusted EPS $2.48 (+12% YoY).
- Repurchased $1.7B of stock in 2022; $900M remaining under authorization.
- Q4 adjusted gross margin improved to 81.0% from 76.8% a year ago.
- Reiterated 2023 outlook: sales growth 9-12% ($5.6-$6.0B); adjusted EPS $2.45-$2.60.

## SEC filing metadata
- accession: 0001099800-23-000003
- form_type: 8-K
- ticker: EW
- cik: 0001099800
- company_name: Edwards Lifesciences Corp
- filed_at: 2023-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/ew-20230131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001099800-23-000003
- JSON: https://secwatch.observer/filing/0001099800-23-000003.json
- Plain text: https://secwatch.observer/filing/0001099800-23-000003.txt

## Key facts
- Earnings Releases
  Edwards Lifesciences Corp reported quarter ended December 31, 2022 results: revenue $1.35 billion, EPS $0.65.
  - Period: quarter ended December 31, 2022
  - Revenue: $1.35 billion
  - EPS: $0.65
  - Result: reported results
  source text: Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended December 31, 2022. Highlights and Outlook • Q4 sales grew 1 percent to $1.35 billion; constant currency 1 sales grew 7 percent • Q4 TAVR sales were flat; constant currency sales grew 5 percent • Q4 EPS of $0.65; adjusted 1 EPS increased 25 percent to $0.64
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm
- Earnings Releases
  Edwards Lifesciences Corp reported first quarter of 2023 results: revenue $1.37 to $1.45 billion, EPS $0.58 to $0.64. Guidance initiated.
  - Period: first quarter of 2023
  - Revenue: $1.37 to $1.45 billion
  - EPS: $0.58 to $0.64
  - Guidance: initiated
  - Result: guidance update
  source text: For the first quarter of 2023, the company projects total sales to be between $1.37 and $1.45 billion, and adjusted EPS of $0.58 to $0.64.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm
- Earnings Releases
  Edwards Lifesciences Corp reported full year 2023 results: revenue $5.6 to $6.0 billion, EPS $2.45 to $2.60. Guidance reaffirmed.
  - Period: full year 2023
  - Revenue: $5.6 to $6.0 billion
  - EPS: $2.45 to $2.60
  - Guidance: reaffirmed
  - Result: guidance update
  source text: Overall, the company is reaffirming the sales guidance it provided at the December investor conference for all product groups. Full year 2023 sales are expected to grow 9 to 12 percent to $5.6 to $6.0 billion. Additionally, the company continues to expect full year 2023 adjusted earnings per share of $2.45 to $2.60.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm
- Earnings Releases
  Edwards Lifesciences Corp reported year ended December 31, 2022 results: revenue $5.38 billion, EPS $2.44.
  - Period: year ended December 31, 2022
  - Revenue: $5.38 billion
  - EPS: $2.44
  - Result: reported results
  source text: Sales for the year ended December 31, 2022, were $5.38 billion, a year-over-year increase of 3 percent, or 8 percent on an underlying basis. Although initial sales expectations for 2022 anticipated a better healthcare environment, the company delivered balanced contributions across each of its product groups and regions. Diluted earnings per share for 2022 were $2.44, while adjusted earnings per share of $2.48 increased 12 percent from the year-ago period.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1099800/000109980023000003/0001099800-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.